The Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: TI stimulation device (nerviox-1000）.
- Who it may be relevant to
- Registry conditions: Obsessive-Compulsive Disorder (OCD). Basic parameters: 18 years — 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Exploring the Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder
Overview
This study aims to evaluate the efficacy of Temporal Interference (TI) stimulation in treating patients with obsessive-compulsive disorder (OCD) and to explore its potential neural mechanisms using magnetic resonance imaging (MRI) and electroencephalography (EEG).
Detailed description
This randomized, blind, multi-phase clinical trial aims to evaluate the efficacy of Temporal Interference (TI) stimulation in patients with treatment obsessive-compulsive disorder (OCD), and to compare the effects of stimulating different brain regions.
The study includes three phases:
* Phase 1: Patients are randomly assigned to receive either sham stimulation, bilateral nucleus accumbens (NAcc) stimulation, or bilateral bed nucleus of the stria terminalis (BNST) stimulation. * Phase 2: Non-responders from Phase 1 enter a second phase, receiving stimulation to the opposite target region. Sham participants are re-randomized to NAcc or BNST. * Phase 3 (Exploratory): Remaining non-responders may opt to receive stimulation targeting the caudate nucleus, the putamen, or the amygdala.
Stimulation is delivered twice daily for 7 days in each phase, followed by follow-up assessments for up to 4 weeks. Comprehensive clinical assessments, self-reported symptom scales, magnetic resonance imaging (MRI), electroencephalography (EEG), and cognitive function tests are conducted before and after each phase to ensure data consistency. Additionally, clinical assessments and self-reported scales are repeated 1 week after the end of each treatment phase.
Interventions
- Device TI stimulation device (nerviox-1000）
The TI stimulation device (nerviox-1000) delivers temporally interfering electrical fields with a 130 Hz envelope frequency, generated by high-frequency carrier waves. The stimulation is applied for 20 minutes per session, with a peak current of 3-4 mA per channel, adjusted based on individual tolerance. The stimulation targets include the nucleus accumbens, bed nucleus of the stria terminalis, amygdala, caudate nucleus, and putamen. Stimulation is administered twice daily, with each treatment p
Primary outcome measures
- Obsessive-compulsive symptoms improvement [Time frame: phase-specific baseline and 1 week after the end of each phase of TI treatment]
Eligibility criteria
Inclusion criteria
- 18-50 years old
- Diagnosis of OCD per DSM-5
- Y-BOCS score ≥20
- Have a documented history of at least two adequate trials of selective serotonin reuptake inhibitors (SSRIs). If currently receiving SSRI treatment, the dosage must be stable for at least 8 weeks prior to enrollment
- With at least 9 years of education
Exclusion criteria
- Any DSM-5 diagnosis other than OCD (except OCPD)
- OCD symptoms too severe to complete assessments
- Received electroconvulsive therapy (ECT) within the past 6 months
- Received other forms of neuromodulation within the past 2 months（see Item 3 for ECT）
- Severe medical illness or seizure risk (e.g., cardiovascular, respiratory conditions)
- Neurological disorders or history of brain injury/surgery
- MRI-incompatible implants (e.g., pacemaker, stents, cochlear implants).
- Current suicidal risk per investigator judgment
- Pregnant or planning pregnancy during the study
- Started structured OCD psychotherapy within 3 months, with expected change during treatment
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Shanghai Mental Health Center — Shanghai
Identifiers
NCT: NCT07113652 · SMHC-OCD-018